NZ755599A - Apoc-ii mimetic peptides - Google Patents

Apoc-ii mimetic peptides

Info

Publication number
NZ755599A
NZ755599A NZ755599A NZ75559918A NZ755599A NZ 755599 A NZ755599 A NZ 755599A NZ 755599 A NZ755599 A NZ 755599A NZ 75559918 A NZ75559918 A NZ 75559918A NZ 755599 A NZ755599 A NZ 755599A
Authority
NZ
New Zealand
Prior art keywords
peptide
apoc
mimetic
seq
mimetic peptide
Prior art date
Application number
NZ755599A
Other languages
English (en)
Inventor
Alan Remaley
Soumitra Ghosh
Madhav Devalaraja
Chih-Hung Lo
Denis Sviridov
Anna Wolska
Original Assignee
Novo Nordisk As
The Us Secretary Department Of Health & Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As, The Us Secretary Department Of Health & Human Services filed Critical Novo Nordisk As
Publication of NZ755599A publication Critical patent/NZ755599A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1722—Plasma globulins, lactoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NZ755599A 2017-01-19 2018-01-19 Apoc-ii mimetic peptides NZ755599A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762448358P 2017-01-19 2017-01-19
US201762476535P 2017-03-24 2017-03-24
US201762476531P 2017-03-24 2017-03-24
PCT/US2018/014532 WO2018136803A1 (en) 2017-01-19 2018-01-19 Apoc-ii mimetic peptides

Publications (1)

Publication Number Publication Date
NZ755599A true NZ755599A (en) 2022-12-23

Family

ID=62908746

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ755599A NZ755599A (en) 2017-01-19 2018-01-19 Apoc-ii mimetic peptides

Country Status (14)

Country Link
US (2) US11136372B2 (https=)
EP (1) EP3571216A4 (https=)
JP (2) JP7353973B2 (https=)
KR (1) KR102700862B1 (https=)
CN (1) CN110831957B (https=)
AU (1) AU2018210404B2 (https=)
BR (1) BR112019014707A2 (https=)
CA (1) CA3050106A1 (https=)
IL (2) IL268093B2 (https=)
MX (1) MX2019008529A (https=)
NZ (1) NZ755599A (https=)
SG (2) SG10201911974UA (https=)
TW (2) TW202130652A (https=)
WO (1) WO2018136803A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202130652A (zh) 2017-01-19 2021-08-16 美國衛生與公眾服務部 Apoc-ii擬肽
CN117580857A (zh) * 2021-06-23 2024-02-20 美国政府(由卫生和人类服务部的部长所代表) Apoc-ii短模拟肽及使用方法
IL316418A (en) * 2022-05-05 2024-12-01 Us Health Short apolipoprotein E mimetic peptides and methods of use
WO2024036145A1 (en) * 2022-08-07 2024-02-15 Protean Bio, Inc. Peptides for beta-cell survival and insulin production

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6156727A (en) * 1996-09-05 2000-12-05 Uab Research Foundation Anti-atherosclerotic peptides and a transgenic mouse model of antherosclerosis
PL372925A1 (en) * 2001-09-28 2005-08-08 Esperion Therapeutics Inc. Prevention and treatment of restenosis by local administration of drug
US7220576B2 (en) * 2002-01-07 2007-05-22 Lifesensors, Inc. Methods and compositions for protein expression and purification
AU2004207444B2 (en) * 2003-01-17 2008-07-31 Merck & Co., Inc. N-cyclohexylaminocarbonyl benzenesulfonamide derivatives
CA2549529A1 (en) * 2003-12-15 2005-06-30 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
CN100567270C (zh) * 2004-02-19 2009-12-09 万有制药株式会社 磺酰胺衍生物
KR101185609B1 (ko) * 2004-07-16 2012-09-24 트러스티즈 오브 터프츠 칼리지 아포리포단백질 ａ１ 미메틱 및 이의 용도
AU2006263332B2 (en) * 2005-06-29 2012-02-23 Hadasit Medical Research Services & Development Ltd. Protein kinase C inhibitors for prevention of insulin resistance and type 2 diabetes
WO2008039843A2 (en) * 2006-09-26 2008-04-03 Lipid Sciences, Inc. Novel peptides that promote lipid efflux
WO2009097584A1 (en) 2008-01-30 2009-08-06 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
US8936787B2 (en) * 2008-04-15 2015-01-20 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Peptides promoting lipid efflux
US20120270771A1 (en) 2009-09-30 2012-10-25 Snu R&Db Foundation Apolipoprotein a-1 mimic peptides, and therapeutic agent for treating hyperlipidemia and diseases related to hyperlipidemia comprising same
ES2859559T3 (es) * 2012-11-06 2021-10-04 Les Hopitaux Univ De Geneve Péptidos miméticos
TW202130652A (zh) 2017-01-19 2021-08-16 美國衛生與公眾服務部 Apoc-ii擬肽
EA201991491A1 (ru) 2017-03-24 2019-12-30 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сервисис Миметические пептиды apoc-ii

Also Published As

Publication number Publication date
IL268093B2 (en) 2024-07-01
IL268093A (en) 2019-09-26
BR112019014707A2 (pt) 2020-04-07
SG10201911974UA (en) 2020-02-27
WO2018136803A1 (en) 2018-07-26
US11136372B2 (en) 2021-10-05
CN110831957B (zh) 2024-02-09
JP2020511425A (ja) 2020-04-16
SG11201906422VA (en) 2019-08-27
TW201835097A (zh) 2018-10-01
IL268093B1 (en) 2024-03-01
US20210324043A1 (en) 2021-10-21
EP3571216A4 (en) 2020-11-04
JP7353973B2 (ja) 2023-10-02
CN110831957A (zh) 2020-02-21
AU2018210404A1 (en) 2019-08-08
US20200140522A1 (en) 2020-05-07
WO2018136803A8 (en) 2019-08-01
US11827690B2 (en) 2023-11-28
TWI788323B (zh) 2023-01-01
IL279831A (en) 2021-03-01
KR102700862B1 (ko) 2024-08-30
CA3050106A1 (en) 2018-07-26
EP3571216A1 (en) 2019-11-27
MX2019008529A (es) 2020-02-07
JP2023116739A (ja) 2023-08-22
TW202130652A (zh) 2021-08-16
KR20190121305A (ko) 2019-10-25
AU2018210404B2 (en) 2022-01-27

Similar Documents

Publication Publication Date Title
EP1853620B1 (en) Antimicrobial hexapeptides
NZ755599A (en) Apoc-ii mimetic peptides
Di Grazia et al. Temporins A and B stimulate migration of HaCaT keratinocytes and kill intracellular Staphylococcus aureus
EP4461811A3 (en) Pharmaceutical composition, comprising human hyaluronidase ph20 variant and drug, for subcutaneous injection
NZ621196A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
EA039105B1 (ru) Катионные нейротоксины
KR20200101953A (ko) 보툴리눔 독소 세포 결합 도메인 폴리펩티드 및 섬유증 연관 장애의 치료를 위한 사용 방법
Puri et al. Immunomodulatory role of neuropeptides in the cornea
HRP20090597T1 (hr) Muteini čimbenika rasta fibroblasta 21
KR20180002710A (ko) 항균 요법
PH12014501642A1 (en) Peptide vaccines for cancers expressing tumor-associated antigens
NZ597306A (en) Mesenchymal stem cell differentiation
RU2013151875A (ru) Модифицированная кислая альфа глюкозидаза с ускоренным процессингом
Conlon et al. Antimicrobial properties of brevinin‐2‐related peptide and its analogs: efficacy against multidrug‐resistant Acinetobacter baumannii
Ouyang et al. High therapeutic index α-helical AMPs and their therapeutic potential on bacterial lung and skin wound infections
Carrera-Aubesart et al. Topoisomeric membrane-active peptides: a review of the last two decades
EP3536325A1 (en) Method for promoting wound healing
EP1969003B8 (en) Uses of a NEUROTROPHIC FACTOR PROTEIN
KR101444261B1 (ko) 왕지네로부터 분리한 신규 스콜로펜드라신ⅰ펩타이드 및 그의 조성물
JP2012507278A5 (https=)
CA2516458C (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
Yang et al. Deleting the first disulphide bond in an arenicin derivative enhances its expression in Pichia pastoris
Abudouwanli et al. AMP-IBP5: A multifunctional antimicrobial peptide for advanced wound healing and inflammatory skin disorders
JP2001186887A (ja) サソリ毒由来の抗菌ペプチド
Harris et al. Antimicrobial peptides from frogs of the Glandirana genus

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: THE UNITED STATES OF AMERICA, US

Effective date: 20210921

Owner name: NOVO NORDISK A/S, DK

Effective date: 20210921

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JAN 2025 BY ANAQUA SERVICES

Effective date: 20231220

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JAN 2026 BY ANAQUA SERVICES

Effective date: 20241219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 JAN 2027 BY ANAQUA SERVICES

Effective date: 20251217